Larry Marnett

A national search is underway for Vanderbilt’s next vice provost for research and innovation. Provost and Vice Chancellor for Academic Affairs C. Cybele Raver has appointed a committee to identify candidates for the university’s new chief research officer, who will begin their appointment early in 2026. Read More

A group of researchers from the lab of Larry Marnett, the Mary Geddes Stahlman Professor of Cancer Research, recently paired a precisely targeted imaging agent to an anticancer agent and found that they could specifically attack cancer cells and not normal cells with it. Their work was performed in collaboration with School of Engineering faculty members Craig Duvall and Rebecca Cook, and was published in Molecular Pharmaceutics in April 2025. Read More

Fluorescent nanoparticles clearly identified colonic adenomas — precursors to colorectal cancer — in mice, and the formulation should translate to clinical use in humans. Read More

Lawrence Marnett and colleagues have demonstrated how two enzymes cooperate to maintain even levels of an important cellular signaling molecule. Read More

Recent advances in imaging technology are enabling Vanderbilt scientists to gain unprecedented views of how molecules, cells and tissues work together, yielding radical new insights into the causes, treatment and prevention of disease. Read More

The Vanderbilt Institute of Chemical Biology (VICB) will hold a Founders’ Celebration mini-symposium on March 28 to acknowledge the contributions of its founders, Lawrence Marnett, PhD, and Ned Porter, PhD, and to celebrate 15-plus years of success as a trans-institutional scientific incubator. Read More

New findings suggest that oxidative stress damages mitochondrial DNA, and they link this damage to a disease state. Read More

Communication and collaboration were major themes of the inaugural Research Enterprise Forum sponsored jointly by Vanderbilt University Medical Center (VUMC) and Vanderbilt University School of Medicine (VUSM) Feb. 3 in Light Hall. Read More

More than a decade after the anti-inflammatory drugs Vioxx and Bextra were pulled from the market because of a heightened risk of heart attack and stroke in some patients, COX-2 inhibitors may be on the verge of a comeback, this time as anti-cancer agents. Read More

In April, when the fiscal separation of Vanderbilt University and Vanderbilt University Medical Center was completed, Larry Marnett—the University Professor of Biochemistry, Chemistry and Pharmacology and Mary Geddes Stahlman Professor of Cancer Research—assumed a new role as the School of Medicine’s first dean of basic sciences, reporting directly to the provost. Read More

Vanderbilt University School of Medicine (VUSM) has launched two new donor societies: the John E. Chapman, M.D. Society, which supports clinical programs and endowed faculty chairs, and the Discovery Circle, which supports the basic sciences. Read More

With the transition of Vanderbilt University Medical Center (VUMC) into a new financial and legal entity now complete, Medical Center leaders view this period as an opportunity to sharpen the organization’s strategic focus. Read More